Metrika

  • citati u SCIndeksu: [1]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:12
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 3 od 3  
Back povratak na rezultate
2014, vol. 33, br. 4, str. 347-355
C-reaktivni protein predviđa progresiju bolesti perifernih arterija kod pacijenata sa dijabetesom tipa 2 - rezultati petogodišnjeg praćenja
aKlinički centar Srbije, Klinika za endokrinologiju dijabetes i bolesti metabolizma, Beograd
bKlinički centar Srbije, Klinika za endokrinologiju dijabetes i bolesti metabolizma, Beograd + Univerzitet u Beogradu, Medicinski fakultet
cInstitute for Gerontology and Palliative Care, Belgrade
dKlinički centar Srbije, Klinika za kardiologiju, Beograd
eKlinički centar Srbije, Klinika za pulmologiju, Beograd

e-adresaljpopovic@beotel.rs
Projekat:
Insulinska rezistencija: poređenje uloge u nastanku i razvoju tipa 2 dijabetesa, aterosklerozne vaskularne bolesti i neurodegenerativnih oboljenja (MPNTR - 175097)
Biomarkeri oštećenja i disfunkcije organa (MPNTR - 175036)

Ključne reči: pedo-brahijalni indeks; C-reaktivni protein; periferna arterijska bolest; tip 2 dijabetesa
Sažetak
Uvod: Prethodne studije su istakle visokosenzitivni C-reaktivni protein (hs-CRP) kao faktor rizika za perifernu arterijsku bolest (PAB) u dijabetesu. Ova studija je imala za cilj da se proceni mogući prediktivni značaj hs-CRP u razvoju i progresiji PAD kod pacijenata sa tipom 2 dijabetesa (T2D). Metode: U studiju je uključeno 80 pacijenata sa prethodnom dijagnozom T2D, starosti 45-70 godina, podeljenih u grupu A (T2D pacijenti sa PAB; n=38) i grupu B (T2D pacijenti bez PAB; n=42). Posle pet godina, pacijenti su podeljeni u podgrupe u zavisnosti od prisustva nove pojave PAB ili progresije prethodno postojeće PAB. Pedo-brahijalni indeks (PBI) korišćen je za dijagnozu PAB, dok je hs-CRP određen nefelometrijski. Rezultati: Našli smo značajno više nivoe hs-CRP u grupi A u odnosu na grupu B, ali samo na početku studije. U okviru grupe A, pacijenti sa kasnijom progresijom PAD (podgrupa A1) imali su najviše nivoe hs-CRP na početku, mada bez značajne razlike u odnosu na podgrupu A2 (neprogresori). Suprotno tome, nivo hs-CRP bio je značajno viši u podgrupi B1 (progresori) u poređenju sa podgrupom B2 (neprogresori) i na početku i na kraju ispitivanja. Od svih ispitivanih metaboličkih parametara, hs-CRP je bio jedini nezavisni prediktor progresije PAD (OR=0,456, 95% CI=0,267-0,7815, p=0,004). Nivo hs-CRP od 2,5 mg/L je utvrđen kao "cut-off" vrednost (specifičnost 75% i senzitivnost 73,3%) sa relativnim rizikom za PAD od 2,93 (95% CI=1,351-6,3629). Zaključak: Naša studija je pokazala da se hs-CRP može koristiti kao pouzdan prediktor progresije PAB kod pacijenata sa T2D.
Reference
*** (2001) The PARTNERS program: A national survey of peripheral arterial disease detection, awareness, and treatment. JAMA, 286: 1317-24
Aboyans, V., Criqui, M.H., Denenberg, J.O., Knoke, J.D., Ridker, P.M., Fronek, A. (2006) Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation, 113(22): 2623-9
Blake, G.J., Ridker, P.M. (2002) Inflammatory bio-markers and cardiovascular risk prediction. Journal of Internal Medicine, 252(4): 283-294
Britton, K.A., Mukamal, K.J., Ix, J.H., Siscovick, D.S., Newman, A.B., de Boer, I.H., Thacker, E.L., Biggs, M.L., Gaziano, J. M., Djoussé, L. (2012) Insulin resistance and incident peripheral artery disease in the Cardiovascular Health Study. Vascular Medicine, 17(2): 85-93
Campbell, M.J., Swinscow, T.D.V., ur. (2002) Statistics at square one 2002. London: Wiley-Blackwell, BMJ Books, pp. 111-145
Diehm, C., Allenberg, J.R., Pittrow, D., et al. (2009) German Epidemiological Trial on Ankle Brachial Index Study Group: Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation, 120: 2053-61
Eknoyan, G. (2008) Adolphe Quetelet (1796-1874): The average man and indices of obesity. Nephrol Dial Transplant, 23: 47-51
Fowkes, F.G.R., Housley, E., Cawood, E.H.H., Macintyre, C.C.A., Ruckley, C.V., Prescott, R.J. (1991) Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology, 20(2): 384-392
Goldhaber, S.Z. (2009) European Atherosclerosis Society screening recommendations for lipoprotein (a) and high-sensitivity C-reactive protein: Double standard or failure of evidence-based medicine. Clinical Chemistry, 55: 378-84
Haffner, S.M., Kennedy, E., Gonzalez, C., Stern, M.P., Miettinen, H. (1996) A prospective analysis of the HOMA model: The Mexico City Diabetes Study. Diabetes Care, 19(10): 1138-1141
Haffner, S.M., Miettinen, H., Stern, M.P. (1997) The homeostasis model in the San Antonio Heart Study. Diabetes Care, 20(7): 1087-1092
Hozawa, A., Ohmori, K., Kuriyama, S., Shimazu, T., Niu, K., Watando, A., Ebihara, S., Matsui, T., Ichiki, M., Nagatomi, R., Sasaki, H., Tsuji, I. (2004) C-reactive protein and peripheral artery disease among Japanese elderly: The Tsurugaya Project. Hypertension Research, 27(12): 955-961
Hull, S.K., Kishman, C.R. J. (2008) What is the best test for peripheral vascular disease?. J Fam Practice, 57: 403-5
Kaptoge, S., di Angelantonio, E., Lowe, G., Pepys, M.B., Thompson, S.G., Collins, R., Danesh, J. (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet, 375(9709): 132-140
Korita, I., Bulo, A., Langlois, M., Blaton, V. (2013) Inflammation markers in patients with cardiovascular disease and metabolic syndrome. Journal of Medical Biochemistry, vol. 32, br. 3, str. 214-219
Leng, G.C., Lee, A.J., Fowkers, F.G.R., Whiteman, M., Dunbar, J., Housley, E., Ruckley, C.V. (1996) Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. International Journal of Epidemiology, 25(6): 1172-1181
Makin, A., Lip, G.Y.H., Silverman, S., Beevers, D.G. (2001) Peripheral vascular disease and hypertension: A forgotten association?. Journal of Human Hypertension, 15(7): 447-454
Mancia, G., Fagard, R., Narkiewicz, K., et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 34:2159-219
Marso, S.P., Hiatt, W.R. (2006) Peripheral arterial disease in patients with diabetes. Journal of the American College of Cardiology, 47(5): 921-929
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C. (1985) Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7): 412-419
Mcdermott, M.M., Guralnik, J.M., Greenland, P., Green, D., Liu, K., Ridker, P.M., Chan, C., Criqui, M.H., Ferrucci, L., Taylor, L.M., Pearce, W.H., Schneider, J.R., Oskin, S.I. (2004) Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial disease. Journal of the American Geriatrics Society, 52(11): 1888-1894
Mcdermott, M.M., Greenland, P., Green, D., Guralnik, J.M., Criqui, M.H., Liu, K., Chan, C., Pearce, W.H., Taylor, L., Ridker, P.M., Schneider, J.R., Martin, G., Rifai, N., Quann, M., Fornage, M. (2003) D-Dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation, 107(25): 3191-3198
Murabito, J.M., D'agostino, R.B., Silbershatz, H., Wilson, W.F. (1997) Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation, 96(1): 44-9
National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (2000) The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication, 4: 7-23, 00-4084
Nilsson, J. (2005) CRP: Marker or maker of cardiovascular disease?. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(8): 1527-1528
Pande, R.L., Perlstein, T.S., Beckman, J.A., Creader, M.A. (2008) Association of insulin resistance and inflammation with peripheral arterial disease: The National Health and Nutrition Examination Survey, 1999 to 2004. Circulation, 118: 33-41
Pearson, T.A., Mensah, G.A., Alexander, R. W., Anderson, J.L., Cannon, R.O. I., Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Myers, G.L., Rifai, N., Smith, S.C., Taubert, K. (2003) Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3): 499-511
Ridker, P.M. (2001) High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 103(13): 1813-8
Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H. (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 97(5): 425-428
Romero-Corral, A., Somers, V.K., Sierra-Johnson, J., Thomas, R.J., Collazo-Clavell, M.L., Korinek, J., Allison, T.G., Batsis, J.A., Sert-Kuniyoshi, F.H., Lopez-Jimenez, F. (2008) Accuracy of body mass index in diagnosing obesity in the adult general population. International Journal of Obesity, 32(6): 959-966
Selvin, E., Erlinger, T.P. (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation, 110, str. 738-43
Signorelli, S.S., Fiore, V., Malaponte, G. (2014) Inflammation and peripheral arterial disease: The value of circulating biomarkers. International Journal of Molecular Medicine, 33(4): 777-783
Vainas, T., Stassen, F.R.M., de Graaf, R., Twiss, E.L.L., Herngreen, S.B., Welten, R.J.Th. J., van den Akker, L.H.J.M., van Dieijen-Visser, M.P., Bruggeman, C.A., Kitslaar, P.J.E.H.M. (2005) C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events. Journal of Vascular Surgery, 42(2): 243-251
van der Meer, I.M., Oei, H.S., Hofman, A., Pols, H.A.P., de Jong, F.H., Witteman, J.C.M. (2006) Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis: The Rotterdam Coronary Calcification Study. Atherosclerosis, 189(2): 464-469
Wallace, T.M., Levy, J.C., Matthews, D.R. (2004) Use and abuse of HOMA modeling. Diabetes Care, 27(6): 1487-1495
Wallenstein, S., Wittes, J. (1993) The power of the Mantel-Haenszel test for grouped failure time data. Biometrics, 49(4): 1077-1097
Willerson, J.T., Cohn, J.N., Wellens, H.J.J., Holmes, D.R. J., ur. (2007) Cardiovascular medicine 2. London: Springer, 1681-703
Williams, J.R. (2008) The Declaration of Helsinki and public health. Bulletin of the World Health Organization, 86(8): 650-651
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2478/jomb-2014-0042
objavljen u SCIndeksu: 17.01.2020.